GW Pharmaceuticals Initiates Phase 1b/2a Clinical Trial for GBM

GW Pharmaceuticals (NASDSQ: GWPH) announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme (GBM). Glioma describes any tumor that arises from the glial tissue of the brain. GBM is a particularly aggressive tumor that forms from abnormal growth of glial tissue. According